1	Phenotypic presentation of family members of ATTRv probands and subsequent disease
2	penetrance
3	
4	Luca Fazzini, MD [*] ; Matteo Castrichini, MD [*] ; Yan Li, PhD; Jose De Melo Jr, MD; Marta
5	Figueiral, MD; Jenny J. Cao, MB; Eric W. Klee, MD; Christian Cadeddu Dessalvi, MD PhD;
6	Martha Grogan, MD; Angela Dispenzieri, MD; Naveen L. Pereira, MD
7	
8	*These authors share first authorship
9	
10	Affiliations: Department of Cardiovascular Medicine (L.F., M.C., J.DM.Jr, M.F., J.J.C., M.G.,
11	N.L.P.); Department of Quantitative Health Science, Division of Clinical Trials and Biostatistics
12	(Y.L.); Department of Quantitative Health Science, Division of Computational Biology (E.W.K.);
13	Division of Hematology (A.D.), Mayo Clinic, Rochester, MN. Department of Medical Sciences
14	and Public Health, University of Cagliari, Cagliari, Italy (L.F, C.C.D.).
15	
16	Short title: ATTRv genetic carriers – phenotype and outcomes
17	
18	Corresponding Author:
19	Naveen L. Pereira, MD; Department of Cardiovascular Medicine and Department of Molecular
20	Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester,
21	MN, 55905. Email: pereira.naveen@mayo.edu; Twitter @nl_pereira

22 Abstract

23	BACKGROUND: Hereditary transthyretin amyloid cardiomyopathy (ATTRv-CM) is being
24	increasingly diagnosed due to enhanced awareness and availability of newer therapeutics.
25	Multiple TTR variants have been described worldwide, but with uncertain disease penetrance.
26	The characteristics and outcomes of "previously undiagnosed" pathogenic-likely pathogenic
27	(P/LP) TTR variant (genotype or G+; cardiac phenotype or P-) carriers are unknown which has
28	important prognostic and therapeutic implications, especially for affected family members. This
29	descriptive study aimed to delineate phenotype and cardiac penetrance in "previously
30	undiagnosed" G+P- family members of ATTRv probands.
31	METHODS: Demographic, electrocardiographic (ECG), genetic, and imaging
32	(echocardiography, cardiac technetium-99m pyrophosphate (PYP) and magnetic resonance
33	imaging) data were analyzed. The prediction effect of selected baseline characteristics for
34	ATTRv-CM development was evaluated. Kaplan-Meier and Cox regression methods were used
35	to describe risk and predictors of ATTRv-CM development in family members.
36	RESULTS: There were 85 G+P- family members identified. Mean age was 48.5±11.7 years,
37	39% were male, 18% had a diagnosis of peripheral neuropathy, 15% with a history of carpal
38	tunnel syndrome, and 4% had atrioventricular block at baseline. Of these, 55 patients had follow-
39	up imaging studies. After a median 6.8-year follow-up, 22% developed ATTR-CM with a 10-
40	year estimated risk of 29.5% (95% CI 7.9-46.0). Cardiac penetrance increased with increasing
41	family member's age. Proband's diagnosis age (p=0.0096) and artificial intelligence (AI)-ECG
42	prediction (p=0.0091) were promising baseline predictors of time to ATTRv-CM development.

- 43 **CONCLUSION:** In previously undiagnosed G+P- ATTRv family members, the incidence of
- 44 subsequent CM is high. Predictors for CM development such as proband's diagnosis age and AI-
- 45 determined ECG probability of ATTR-CM require further investigation.
- 46
- 47 Keywords: transthyretin amyloidosis; phenotype; cardiac; cardiomyopathy

49 NON-STANDARD ABBREVIATONS AND ACRONYMS

- 50 AI artificial intelligence AI
- 51 **ATTR** transthyretin amyloidosis
- 52 AUC area under the curve
- 53 CA cardiac amyloidosis
- 54 CI confidence interval
- 55 CM cardiomyopathy
- 56 CV cross-validation
- 57 **cMRI** cardiac magnetic resonance
- 58 ECG electrocardiographic
- 59 HR hazards ratio
- 60 LV left ventricular
- 61 **PR** precision recall
- 62 **PYP** pyrophosphate
- 63
- 64

65 Introduction

66	Cardiac amyloidosis (CA) is a well-known cause of heart failure and life-threatening disease. ¹⁻³
67	Early diagnosis of transthyretin amyloidosis (ATTR) which is a common cause of CA has
68	become especially relevant given recent advances in diagnosis and therapy. ⁴ Cardiomyopathy
69	(CM) due to ATTR is classified as either wild-type (ATTRwt-CM) or hereditary (ATTRv-CM). ⁵
70	Hereditary ATTR is an autosomal-dominant disease and over 130 TTR variants have been
71	identified that have ethnic and geographical specific distribution. ⁶⁻⁸ Different TTR genotypes are
72	associated with varying phenotypes. ⁹⁻¹¹ The correlation between genetic heterogeneity,
73	variability in disease onset, and expression remains an active area of investigation. ¹²
74	Genetic testing is recommended in patients diagnosed with ATTR-CM in order to
75	distinguish between wild-type and hereditary disease. ^{4,13-15} Identifying a pathogenic (P) or likely-
76	pathogenic (LP) variant not only enables a diagnosis of ATTRv-CM but also allows for cascade
77	testing in first-degree relatives. ¹⁶ However, managing genotype-positive (G+, carriers of a P or
78	LP variant) phenotype-negative (P-, individuals without evidence of structural heart disease)
79	remains a challenge due to a lack of information on the natural course of the disease and the
80	uncertain cardiac penetrance of these TTR variants. Understanding outcomes and identifying
81	high risk individuals will inform strategies for not only monitoring but also potentially treating
82	TTR genetic (G+P-) carriers. The purpose of this study was to evaluate the natural history,
83	cardiac disease penetrance, and predictors of the development of ATTRv-CM in previously
84	undiagnosed TTR G+P- individuals.

86 Methods

87 *Study population*

88	The institutional review board of the Mayo Clinic Foundation approved this study which was a
89	single-center, observational, and retrospective study. Among the overall population affected by
90	amyloidosis followed at Mayo Clinic, Rochester, previously undiagnosed family members of
91	probands who were diagnosed with ATTRv and underwent genetic testing were identified from
92	January 1998 to October 2023. Those with P/LP TTR variants without evidence of ATTR-CM at
93	baseline screening (G+P-) were included in the study. P- individuals were defined as those with
94	the absence of echocardiographic evidence of ATTR-CM as previously described ¹⁷ and/or
95	negative pyrophosphate (PYP) scintigraphy. Pertinent demographic, clinical,
96	electrocardiographic (ECG), and imaging data closest to the date of genetic testing for these
97	patients were extracted from the electronic medical record. Patients without cardiac imaging at
98	baseline were excluded since the baseline cardiac phenotype could not be determined. The
99	population was divided into two groups based on the development of CM during follow-up.
100	
101	Genetic testing
102	Genomic DNA obtained from submitted samples was enriched for targeted regions using a
103	hybridization-based protocol. Sequence analysis and deletion/duplication testing of the TTR gene
104	were performed. A bi-directional sequence analysis was performed to test for the presence of
105	variants in all coding regions and intron/exon boundaries of the TTR gene. A P/LP variant in the
106	TTR gene was defined as per the American College of Medical Genetics and Genomics (ACMG)
107	standard criteria. ¹⁸

109 Cardiomyopathy diagnosis during follow-up

110	The criteria used to diagnose ATTR-CM during follow-up were as follows: 1) Standard
111	previously used echocardiographic criteria (at least two of the following features): ¹⁷ normal left
112	ventricular (LV) wall thickness at baseline (\leq 13mm) that became abnormal during follow-up;
113	normal filling pressures (E/e` \leq 8) that became abnormal, normal atria size at baseline that
114	evolved to biatrial enlargement at follow-up; and normal LV global longitudinal strain (<-18%)
115	that subsequently became abnormal. 2) a normal cardiac magnetic resonance (cMRI) scan at
116	baseline which during follow-up demonstrated late gadolinium enhancement and increased
117	extracellular volume consistent with ATTR-CM 3) a negative baseline PYP scintigraphy that
118	became positive during follow-up. Patients were considered not to have developed ATTR-CM if
119	they had any negative follow-up imaging study.
420	

120

121 Artificial intelligence-enabled electrocardiography

A previously developed and validated artificial intelligence (AI) algorithm to diagnose CA was applied to the baseline ECG of the G+P- carriers.^{19,20} An AI ECG was considered positive when the probability threshold to detect patients with CA by the Youden index was 0.485 or higher.

126 Statistical analysis

127 Descriptive statistics were used to summarize the characteristics of the study population.

128 Continuous variables are reported as mean (standard deviation, SD) or median (interquartile

range [IQR]), and categorical variables are reported as proportions. To evaluate if clinical and

130 echocardiographic characteristics are changed between baseline and follow-up, continuous

131 variables were tested using paired two-sided t-tests, while binary variables were tested if their

132 proportional difference between baseline and follow-up is different from 0. Kaplan-Meier method was used to estimate time-to-event models. Patients without events were censored at the 133 last follow-up. To study the prediction effect of selected baseline characteristics, first we fit the 134 Firth's penalized logistic regressions using the CA development as a dependent variable and the 135 baseline characteristics as independent variables. Next, we aimed to study if there is a synergistic 136 effect of those baseline variables. To retain the sample size of 55, missing values of baseline 137 variables were imputed by median values from corresponding groups (developing or not 138 developing CA). Next, we combine these selected baseline characteristics using Ridge logistic 139 140 regression. Therefore, the predictor of this Ridge logistic model is the optimal composite score of those baseline variables. We used precision-recall (PR) curve analysis to evaluate the predicting 141 effect of the composite score for CA development. Specifically, 11-fold cross-validation (CV) 142 was used when calculating the area under the curve (AUC), since the score was derived from an 143 estimated model and was needed to protect against overfitting. To improve the estimated 144 performance of the regression model, we repeated the CV procedure 100 times. Univariable Cox 145 proportional hazard models were performed to evaluate the risk of developing overt CA. The 146 Hazard Ratios (HR) and the corresponding 95% Confidence Intervals (CI) were reported. The 147 TRR penetrance on ATTR-CM in different age groups were calculated and their 95% CI were 148 estimated. For all tested hypotheses, the significance level of 0.05 was considered and multiple 149 testing was adjusted by the Bonferroni correction method. All analyses were performed on R 150 151 version 4.2.2.

153 Results

Among the overall ATTR population reviewed (n=1802), 85 carriers were confirmed to have P/LP TTR variants without evidence of CM at the time of genetic testing. Specifically, 80 patients had normal echocardiography and 5 patients had negative PYP scintigraphy alone, 29 patients had both negative echocardiography and PYP scintigraphy. In addition, cMRI at baseline was normal in 4 patients.

159

160 Baseline characteristics of TTR genotype-positive phenotype-negative individuals

161 Baseline characteristics of the patient population are reported in **Table 1**. The mean age was

162 48.5±11.7 years, 39% were males, and 91% were White. Comorbidities included spinal stenosis

163 (2%), chronic kidney disease (1%), peripheral neuropathy (18%), and bilateral carpal tunnel

syndrome (15%). One patient had undergone permanent pacemaker implantation and 2% had a

prior history of syncope. Troponin levels were elevated in 17% of patients, and median NT-

166 proBNP in the cohort was normal at 51 pg/ml (IQR 25-88). ECG abnormalities included

167 atrioventricular block (n=3), atrial fibrillation (n=3), low voltage (n=1) and pseudo-infarct

168 pattern (n=3). The median AI-enabled ECG probability of CA was 6.3% (IQR 1.9-19.3), and five

169 patients had an AI-ECG probability above the threshold.

None of the patients met the pre-defined echocardiographic criteria for ATTR-CM. Mean
septal and posterior wall thickness were 9.3±1.5 and 9.1±1.4 mm respectively with a mean LV
end-diastolic volume of 127 ml and LV ejection fraction (LVEF) of 62.6±7.4%. A sensitive
indicator of systolic dysfunction, LV global longitudinal strain was slightly reduced (range -15%
to -17%) in 11% of patients (n=7/61) but overall mean values were normal at -20.5±2.6%. Left

175	atrial dilation was reported in 10% of subjects with a mean left atrium volume index that was
176	normal at 28±8.5 ml/m2. Mean LV filling pressures were not significantly elevated (7.7 \pm 2.7).
177	The TTR P/LP variants observed in our population are listed in Table S1 with Val30Met being
178	the most prevalent (30%), followed by Thr60Ala (28%), Val122Ile (9%), and Ile107Val (7%).
179	
180	Clinical progression in TTR genotype-positive phenotype-negative carriers
181	Among the 85 G+/P- carriers, follow-up clinical and imaging studies were available in 55
182	patients. Clinical progression in this cohort is described in Table 2. Over a median follow-up
183	period of 6.8 years (IQR $4.1 - 9.7$), the risk of developing peripheral neuropathy during follow-
184	up was 25.5% (95%CI: 8.9, 42.1) as compared to baseline (p=0.004). Specifically, there were an
185	additional 4 patients who developed spinal stenosis, 7 bilateral carpal tunnel syndrome, 5 atrial
186	fibrillation, and 6 syncope during follow-up as compared to baseline. Among the patients (n=24)
187	who were diagnosed with peripheral neuropathy, 15 underwent skin/nerve biopsy, and 2 patients
188	stained positive for amyloid deposition. Small interfering RNA or antisense oligonucleotide
189	therapy was initiated in 12 patients.
190	
191	Cardiac disease penetrance in TTR genotype-positive phenotype-negative carriers
192	Within this group, 53 underwent echocardiography, and 2 patients had a PYP scan alone, 18 had
193	both PYP scintigraphy and echo, and 4 had both cMRI and echo at baseline. During follow-up,
194	12 (22%) of the 55 patients developed ATTRv-CM. Specifically, 5 patients developed a positive
195	PYP scan, 6 patients were diagnosed based on the change in predefined echocardiography
196	criteria and 1 patient developed cMRI features of CA. The disease-free at 10 years was estimated
197	by the Kaplan-Meier method, and the 10-year risk of developing overt ATTRv-CM was 29.5%

198	(95% CI: 7.9, 46.0, Figure 1). Additionally, cardiac penetrance was assessed among different
199	age groups (Table 3). The penetrance increases as age increases. For the groups \leq 50 years, 50-
200	60 years, 60-70 years, and > 70 years, there are 11% (95% CI: 3%, 33%), 13% (95% CI: 4%,
201	38%), 33% (95% CI: 15%, 58%), and 43% (95% CI: 16%, 75%) patients developed ATTRv-CM
202	at the end of the follow-up period, respectively. We also studied cardiac penetrance among
203	different genetic variants. The age distribution is similar among the three most prevalent variants.
204	The median ages at the end of follow-up are 61.0, 60.5, and 59.0 for patients who have
205	Val130Met, Thr60Ala, and Val122Ile variants, respectively. The cardiac penetrance for the three
206	genetic variants are 7% for Val130Met, 33% for Thr60Ala, and 40% for Val122Ile (Table S2).
207	
208	Echocardiographic changes in TTR genotype-positive phenotype-negative carriers
209	Echocardiographic progression in this cohort is described in Table 2. Overall, we observed a
210	decrease in LVEF (p=0.014), an increase in septal wall thickness (p=0.037), and an increase in
211	left atrium dilation proportion (p=0.016). Posterior wall thickness, left atrium volume index,
212	bilateral dilation, E/e`, and LV GLS did not significantly change. Notably, while at baseline no
213	patients had abnormal wall thickness, 4 patients had abnormal septal wall thickness and 2
214	patients had abnormal posterior wall thickness during follow-up.
215	In the 12 patients diagnosed with ATTRv-CM (Table 4), the mean LVEF remained
216	normal ($60.3\pm 5.3\%$) but was reduced as compared to baseline (p=0.026). There was an increase
217	in the mean septal wall (9.4 \pm 1.0 mm to 12.0 \pm 3.3 mm, p=0.019) and mean posterior wall
218	thickness (9.8 \pm 1.4 mm to 10.9 \pm 3.3 mm, p=0.147). There was a significant increase in the
219	proportion of ATTRv-CM patients who developed left atrium dilation at follow-up compared to
220	baseline (63.6% vs 9.1%, p=0.008). Notably, 3 developed biatrial dilation during follow-up

- 221 (p=0.038). Among the 43 patients who did not develop ATTRv-CM by pre-specified criteria
- 222 (Table S3), there were expectedly no differences between any of the echocardiographic
- 223 parameters during follow-up as compared to baseline.
- 224

225 Predictors of cardiac disease penetrance

226 Baseline characteristics were selected to evaluate for an association with ATTRv-CM

development using Firth's penalized logistic regression (Table S4). The proband's age at the time

of diagnosis (p-value = 0.0076) and AI-ECG amyloid probability (p-value = 0.0041) were

associated with the development of ATTRv-CM. Next, a composite score was calculated that

230 combined all the selected baseline characteristics to evaluate its predictive value for ATTRv-CM

231 development. A Ridge penalized logistic regression was fitted using the disease development as a

dependent variable and those baseline characteristics as independent variables. We use the

estimated predictor of the fitted model as the composite score. We use the precision-recall

analysis to evaluate the prediction performance of the composite score. The estimated AUC

under the precision-recall curve from repeated cross-validation was 0.65, which indicated a

236 prediction effect of those variables for ATTRv-CM development.

By fitting Cox proportional-hazard regressions, patient's age (HR: 1.09, 95%: 1.01, 1.17,

238 p=0.0246), proband's age of diagnosis (HR: 0.91, 95%: 0.86, 0.98, p=0.0096), NTproBNP (HR:

239 1.00, 95%: 1.00, 1.01, p=0.0119), scaled AI ECG probability of ATTRv-CM (HR: 1.04, 95% CI:

240 1.01-1.07, p=0.0091), proband's neurological involvement (HR: 0.23, 95% CI: 0.07-0.83,

241 p=0.0244), and NTproBNP (HR: 1.01, 95% CI: 1.00-1.01, p=0.0187) were associated with the

time to ATTR-CM development (Table 5). However, after adjusting for multiple testing these

243 associations were not statistically significant.

244

245 **Discussion**

This study, the largest of its kind to describe ATTRv G+/P- carriers, also sheds light on the 246 247 complex dynamics of cardiac disease penetrance and expressivity in ATTRy, that could help counsel these individuals and may guide informed decision-making regarding the timing of 248 initiating medical therapy. The observed cardiac penetrance rate of 22% over a median 6.8-year 249 follow-up period and its age-dependency, underscores the latency and variable nature of disease 250 manifestation among TTR variant carriers lacking structural evidence of CM at baseline. This 251 252 study also provides insight into the evolution of cardiac morphology and function as assessed by echocardiography in this genetically diverse group of TTR carriers. Moreover, we observed that 253 the proband's age of diagnosis impacts on disease penetrance in their family members, the older 254 255 the age at diagnosis of the proband, the lower the probability of developing amyloidosis in family members. We also generated the hypothesis of the potential use of AI-enabled ECG 256 screening at baseline as a non-invasive method for predicting ATTRv-CM penetrance. The AI 257 ECG screening tool offers a promising approach to risk stratification, perhaps enabling a 258 precision medicine approach to attenuate disease progression and improve patient outcomes. 259 260 Larger studies are needed to validate our exploratory observations.

Among genetic cardiomyopathies, the time from being diagnosed with a P/LP to developing the disease is highly variable and often undefined.²¹⁻²⁴ A Large dataset demonstrated that the frequency of a P/LP *TTR* variant is not so rare (approximately 1 in 1000 individuals).²⁵ The penetrance of ATTRv manifesting specifically as peripheral neuropathy is also variable in different geographical regions and among families.²⁶⁻²⁸ Similarly, ATTRv peripheral neuropathy is also characterized by incomplete cardiac penetrance and variable expressivity.⁴ A relationship

267 between age at diagnosis and disease penetrance has been described in this disease, although the underlying age-dependent mechanisms are unknown.²⁹ Male sex has also been associated with 268 an increased risk for peripheral neuropathy disease penetrance in ATTRV30M carriers.²⁶ 269 270 The natural history of *TTR* variant carriers has been previously described in results of an observational survey but was based on occurrence of symptoms alone.³⁰ The outcomes of 271 "asymptomatic" patients (defined as absence of heart failure symptoms) with echocardiographic 272 evidence of ATTR-CM at baseline have also been previously described,³¹ and individuals carriers 273 of a P/LP TTR variant enrolled in the United Kingdom Biobank were found to be at higher risk 274 of heart failure.²⁵ However, information regarding ATTRv cardiac disease penetrance and 275 expressivity based on cardiac imaging in G+/P- family members is largely unknown.³² In the 276 Atherosclerosis Risk in Communities study, V122I TTR variant Black carriers (n=124) were 277 278 found to be at an increased risk of incident heart failure as compared to non-carriers over 21.5 years of follow-up.³³ Recently, V122I carriers who were predominately Black were described to 279 have a higher risk of all-cause mortality and heart failure hospitalizations, particularly driven by 280 heart failure with reduced EF, compared to non-carrier controls.³⁴ However, in both these studies 281 whether CA was present at baseline and whether heart failure occurred due to CA or other causes 282 such as coronary artery disease or hypertension is unknown. Furthermore, White subjects were 283 not studied given that the V122I variant is predominantly present in Blacks. Our study addresses 284 these limitations by describing the disease-specific natural history of hereditary ATTR confirmed 285 286 by imaging in G+P- patients who mostly had variants other than V122I. It is relevant to highlight that 18% of our overall cohort of family members had a history 287 of clinically diagnosed peripheral neuropathy at baseline and the nerve/skin biopsy, when 288 289 performed, was most likely to be negative for amyloid deposition. The lack of sensitivity of the

290 nerve/skin biopsies for amyloid maybe due to the multifocal amyloid deposition process, the early stage of the disease, and the possibility of peripheral neuropathy due to related 291 comorbidities (three patients with negative biopsy had concomitant diabetes mellitus).^{35,36} 292 293 However, the high prevalence and progression of peripheral neuropathy underscores the potential systemic nature of ATTRv amyloidosis and the importance of considering extracardiac 294 manifestations in the risk assessment of these individuals. Despite we were not powered to 295 predict the development of cardiac disease based on extracardiac manifestation, the presence of 296 these extracardiac clinical manifestations should always raise the suspicion of systemic 297 298 amyloidosis.

Increased LV wall thickness, a classic echocardiographic feature of CA, and a reduction 299 in LVEF were observed but the latter variable remained within normal limits in G+/P- family 300 301 members LVEF. Sensitive echocardiographic deformation parameters such as myocardial strain have been proposed to detect early involvement of the heart in amyloidosis. However, these 302 values remained within the normal range in our population. Among the seven patients with 303 abnormal global longitudinal strain at baseline, ATTRv-CM was diagnosed only in one case 304 during follow-up. Therefore, global longitudinal strain may not be indicative of subsequent 305 306 cardiac involvement in our population. Myocardial deformation echocardiographic imaging has primarily been validated in cohorts with some grade of increased myocardial wall thickness and 307 whether this echocardiographic parameter could be useful in the early identification of ATTR-308 CM in a G+/P- population prior to this study is unknown.³⁷ Moreover, we found that the age at 309 which the proband is diagnosed with ATTRv influences cardiac penetrance in family members. 310 This age-dependent penetrance finding in the proband aligns with the recommendation of 311

beginning disease assessment in family members, 10 years before the affected proband's age of
disease onset.^{10,38}

It is unknown whether and when to initiate newer therapy for ATTR amyloidosis in G+P-314 patients representing an unmet need in clinical practice. Our findings suggest that G+P-315 individuals with a positive AI-ECG and with an affected proband who was diagnosed at a 316 younger age have a higher probability of developing CM. Patients with high AI-ECG probability 317 may warrant more frequent follow-up with multimodality imaging, and cardiac biopsy may be 318 indicated if imaging is inconclusive especially if patients are symptomatic to consider initiation 319 320 of therapy. 321 Patient's perspective 322 Returning genetic testing results can be emotionally and logistically challenging for both family 323 members and healthcare providers given the uncertainty in outcomes. Genetic testing results 324 might have a profound impact on individuals and families, highlighting the need for such studies 325 and high-touch methods such as one-on-one genetic counseling. We hope our study with others 326 will help inform not only the clinicians who will encounter these patients but also the patients 327 themselves. 328

329

330 *Limitations*

A limitation of our study includes a relatively small sample size which is an inherent limitation of rare diseases, although it is the largest study of *TTR* P/LP variant carriers with longitudinal cardiac imaging follow-up that provides information on cardiac penetrance of ATTRv in the absence of clinically discernible cardiac disease. Although a longer period of follow-up may

335	have yielded a higher cardiac disease penetrance, this study with a median 6.8-year follow-up			
336	period provides a reasonable estimate of disease risk. Furthermore, less than half had PYP			
337	scintigraphy, largely driven by the period of the study, which is known to be more sensitive than			
338	echocardiograms. Perhaps the cardiac phenotype penetrance might be even higher than what we			
339	observed. Larger cohorts will be required to validate our findings such as the use of AI-ECG to			
340	identify those at risk for ATTRv-CM development to enable early disease detection and			
341	intervention.			
342				
343	Conclusion			
344	In conclusion, the 10-year estimated risk of ATTRv-CM development in G+P- family members			
345	is high at 29.5%, and the most common echocardiographic features that characterize CM			
346	development are increased LV wall thickness and left atrial dilation. The risk of developing CM			
347	in ATTRv family members appears to be proband age-of-disease dependent and could be			
348	predicted by baseline AI ECG. These findings describe the high incidence of CA and the			
349	possibility of risk stratifying ATTRv G+P- patients not only to assist in counseling family			
350	members but also to provide guidance to clinicians regarding the timing of initiating appropriate			
351	but expensive therapy for ATTRv-CM. Further validation of our exploratory analysis results in			
352	larger cohorts is needed.			
353				
354	Sources of Funding			
355	Dr. Luca Fazzini received a grant funded by the Italian Society of Cardiology and Bruno			
356	Farmaceutici during the research fellowship at Mayo Clinic, Rochester.			

358 Disclosures

359 None.

360

361 Supplemental Material

362 Tables S1-S4

363 **References**

- 1. Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and
- infiltrative cardiomyopathies: Part 1 of a 2-Part Series. *J Am Coll Cardiol*. 2018;71:1130-
- 366 1148. doi: 10.1016/j.jacc.2018.01.016
- 2. Pereira NL, Grogan M, Dec GW. Spectrum of restrictive and
- 368 infiltrative cardiomyopathies: Part 2 of a 2-Part Series. *J Am Coll Cardiol*. 2018;71:1149-
- 369 1166. doi: 10.1016/j.jacc.2018.01.017
- 370 3. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. *Cardiovasc Res.*
- 371 2023;118:3517-3535. doi: 10.1093/cvr/cvac119
- 4. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO,
- 373 Dember LM, Frantz JG, Hershberger RE, Maurer MS, et al. 2023 ACC expert consensus
- decision pathway on comprehensive multidisciplinary care for the patient with cardiac
- amyloidosis. *J Am Coll Cardiol*. 2023;81:1076-1126. doi: doi:10.1016/j.jacc.2022.11.022
- 5. Buxbaum JN, Dispenzieri A, Eisenberg DS, Fändrich M, Merlini G, Saraiva MJM,
- 377 Sekijima Y, Westermark P. Amyloid nomenclature 2022: update, novel proteins, and
- 378 recommendations by the International Society of Amyloidosis (ISA) Nomenclature
- Committee. *Amyloid*. 2022;29:213-219. doi: 10.1080/13506129.2022.2147636
- 380 6. Mutations in hereditary amyloidosis. [Internet]. 2023. Available from:
- 381 <u>http://www.amyloidosismutations.com/</u>. In.
- 382 7. Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-
- dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause
- of significant heart disease in elderly African Americans. *Genet Med.* 2017;19:733-742.
- 385 doi: <u>https://doi.org/10.1038/gim.2016.200</u>

- 386 8. Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional
- 387 implications. *Annu Rev Nutr*. 1994;14:495-533. doi:
- 388 10.1146/annurev.nu.14.070194.002431
- 389 9. Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP,
- Lenihan DJ, Gottlieb SS, Shah SJ, et al. Genotype and phenotype of transthyretin cardiac
- amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *J Am Coll Cardiol*.
- 392 2016;68:161-172. doi: 10.1016/j.jacc.2016.03.596
- 10. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ,
- 394 Nair AP, Nativi-Nicolau J, Ruberg FL. Cardiac amyloidosis: Evolving diagnosis and
- 395 management: A scientific statement from the American Heart Association. *Circulation*.

396 2020;142:e7-e22. doi: 10.1161/cir.000000000000792

- 11. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M,
- 398 Grigioni F, Leone O, et al. Disease profile and differential diagnosis of hereditary
- transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian

400 perspective. *Eur Heart J.* 2013;34:520-528. doi: 10.1093/eurheartj/ehs123

- 401 12. Sekijima Y. Hereditary transthyretin amyloidosis. In: Adam MP, Feldman J, Mirzaa GM,
- 402 Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, eds. *GeneReviews*(®).
- 403 Seattle (WA): University of Washington, Seattle. Copyright © 1993-2024, University of
- 404 Washington, Seattle. GeneReviews is a registered trademark of the University of
- 405 Washington, Seattle. All rights reserved.; 1993.
- 406 13. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio
- 407 ALP, Damy T, Eriksson U, et al. Diagnosis and treatment of cardiac amyloidosis. A

408		position statement of the European Society of Cardiology Working Group on Myocardial
409		and Pericardial Diseases. Eur J Heart Fail. 2021;23:512-526. doi: 10.1002/ejhf.2140
410	14.	Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, Knebel F, Meder
411		B, Morbach C, Nagel E, et al. Diagnosis and treatment of cardiac amyloidosis: position
412		statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110:479-506.
413		doi: 10.1007/s00392-020-01799-3
414	15.	Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R,
415		Narayan J, Swiggum E, Venner CP, et al. Canadian Cardiovascular Society/Canadian
416		Heart Failure Society joint position statement on the evaluation and management of
417		patients with cardiac amyloidosis. Can J Cardiol. 2020;36:322-334. doi:
418		10.1016/j.cjca.2019.12.034
419	16.	Musunuru K, Hershberger RE, Day SM, Klinedinst NJ, Landstrom AP, Parikh VN,
420		Prakash S, Semsarian C, Sturm AC. Genetic testing for inherited cardiovascular diseases:
421		A scientific statement from the American Heart Association. Circ Genom Precis Med.
422		2020;13:e000067. doi: 10.1161/hcg.000000000000067
423	17.	Cuddy SAM, Chetrit M, Jankowski M, Desai M, Falk RH, Weiner RB, Klein AL, Phelan
424		D, Grogan M. Practical points for echocardiography in cardiac amyloidosis. J Am Soc
425		Echocardiogr. 2022;35:A31-a40. doi: 10.1016/j.echo.2022.06.006
426	18.	Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon
427		E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a
428		joint consensus recommendation of the American College of Medical Genetics and
429		Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-424.
430		doi: 10.1038/gim.2015.30

- 431 19. Grogan M, Lopez-Jimenez F, Cohen-Shelly M, Dispenzieri A, Attia ZI, Abou Ezzedine
- 432 OF, Lin G, Kapa S, Borgeson DD, Friedman PA, et al. Artificial intelligence-enhanced
- 433 electrocardiogram for the early detection of cardiac amyloidosis. *Mayo Clin Proc.*
- 434 2021;96:2768-2778. doi: 10.1016/j.mayocp.2021.04.023
- 435 20. Harmon DM, Mangold K, Suarez AB, Scott CG, Murphree DH, Malik A, Attia ZI,
- 436 Lopez-Jimenez F, Friedman PA, Dispenzieri A, et al. Postdevelopment performance and
- 437 validation of the artificial intelligence-enhanced electrocardiogram for detection of
- 438 cardiac amyloidosis. *JACC: Advances*. 2023;2:100612. doi:
- doi:10.1016/j.jacadv.2023.100612
- 440 21. Topriceanu CC, Pereira AC, Moon JC, Captur G, Ho CY. Meta-analysis of penetrance

and systematic review on transition to disease in genetic hypertrophic cardiomyopathy.

442 *Circulation*. 2024;149:107-123. doi: 10.1161/circulationaha.123.065987

- 443 22. Shah RA, Asatryan B, Sharaf Dabbagh G, Aung N, Khanji MY, Lopes LR, van
- 444 Duijvenboden S, Holmes A, Muser D, Landstrom AP, et al. Frequency, penetrance, and
- 445 variable expressivity of dilated cardiomyopathy-associated putative pathogenic gene
- 446 variants in UK Biobank participants. *Circulation*. 2022;146:110-124. doi:
- 447 10.1161/circulationaha.121.058143
- 448 23. McGurk KA, Zhang X, Theotokis P, Thomson K, Harper A, Buchan RJ, Mazaika E,
- 449 Ormondroyd E, Wright WT, Macaya D, et al. The penetrance of rare variants in
- 450 cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance
- 451 for secondary findings. *Am J Hum Genet*. 2023;110:1482-1495. doi:
- 452 10.1016/j.ajhg.2023.08.003

453	24.	Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyopathy: practical
454		implications for heart failure management. Nat Rev Cardiol. 2020;17:286-297. doi:
455		10.1038/s41569-019-0284-0
456	25.	Aung N, Nicholls HL, Chahal CAA, Khanji MY, Rauseo E, Chadalavada S, Petersen SE,
457		Munroe PB, Elliott PM, Lopes LR. Prevalence, cardiac phenotype, and outcomes of
458		transthyretin variants in the UK Biobank population. JAMA Cardiol. 2024. doi:
459		10.1001/jamacardio.2024.2190
460	26.	Gorram F, Olsson M, Alarcon F, Nuel G, Anan I, Planté-Bordeneuve V. New data on the
461		genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in
462		Sweden. Amyloid. 2021;28:84-90. doi: 10.1080/13506129.2020.1841623
463	27.	Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V.
464		Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the
465		Swedish population. Amyloid. 2008;15:181-186. doi: 10.1080/13506120802193720
466	28.	Planté-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M,
467		Said G, Bonaïti-Pellié C. Genetic study of transthyretin amyloid neuropathies: carrier
468		risks among French and Portuguese families. J Med Genet. 2003;40:e120. doi:
469		10.1136/jmg.40.11.e120
470	29.	Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol.
471		2011;10:1086-1097. doi: 10.1016/s1474-4422(11)70246-0
472	30.	Coelho T, Conceição I, Waddington-Cruz M, Keohane D, Sultan MB, Chapman D,
473		Amass L. A natural history analysis of asymptomatic TTR gene carriers as they develop
474		symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes
475		Survey (THAOS). Amyloid. 2022;29:228-236. doi: 10.1080/13506129.2022.2070470

476	31.	Gonzalez-Lopez	E. Escobar-Loi	pez L. Obici L.	Saturi G. Bezard	M. Saith SE.
			_,			,

- 477 AbouEzzeddine OF, Mussinelli R, Gagliardi C, Kharoubi M, et al. Prognosis of
- transthyretin cardiac amyloidosis without heart failure symptoms. *JACC CardioOncol*.
- 479 2022;4:442-454. doi: 10.1016/j.jaccao.2022.07.007
- 480 32. Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J,
- 481 Alexander K, Masri A. Prevalence and outcomes of p.Val142Ile *TTR* amyloidosis
- 482 cardiomyopathy: A systematic review. *Circ Genom Precis Med.* 2021;14:e003356. doi:
- 483 doi:10.1161/CIRCGEN.121.003356
- 484 33. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH,
- Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant

486 in elderly Black Americans. *New Engl J Med*. 2015;372:21-29. doi:

- 487 10.1056/NEJMoa1404852
- 488 34. Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW, Khan SS,
- 489Rich SS, Mosley TH, Levitan EB, et al. Cardiovascular burden of the V142I transthyretin

490 variant. *JAMA*. 2024;331:1824-1833. doi: 10.1001/jama.2024.4467

- 491 35. Freeman R, Gonzalez-Duarte A, Barroso F, Campagnolo M, Rajan S, Garcia J, Kim JY,
- 492 Wang N, Orellana L, Gibbons C. Cutaneous amyloid is a biomarker in early ATTRv
- 493 neuropathy and progresses across disease stages. Ann Clin Transl Neurol. 2022;9:1370-
- 494 1383. doi: 10.1002/acn3.51636
- 495 36. Said G. Indications and usefulness of nerve biopsy. *Arch Neurol.* 2002;59:1532-1535.
- doi: 10.1001/archneur.59.10.1532
- 497 37. Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J,
- 498 Kuznetsova T, Voigt JU. Echo parameters for differential diagnosis in cardiac

- 499 amyloidosis: A head-to-head comparison of deformation and nondeformation parameters.
- 500 *Circ Cardiovasc Imaging*. 2017;10:e005588. doi: 10.1161/circimaging.116.005588
- 501 38. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid
- 502 cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019;73:2872-2891.
- 503 doi: 10.1016/j.jacc.2019.04.003

504

505

Overall

507 Table 1. Baseline characteristics of the overall G+/P- ATTRv cohort.

508

	(n=85)
Age (years)	48.5 (11.7)
Male sex n (%)	33 (39)
White n (%)	77 (91)
Proband's cardiac involvement n (%)	47 (55)
Proband's neurological involvement n (%)	51 (60)
Proband`s organ involvement unknown n (%)	10 (12)
First-degree relatives, n (%)	63 (74)
Second-degree relatives, n (%)	22 (26)
Blood test	
$\overline{\text{WBC}(\text{x}10^3/\mu\text{L})^{a}}$	6.1 (5.1-6.9)
Hb (g/dL)	13.9 (1.4)
$\overline{\text{PLT}(x10^3/\mu\text{L})^{a}}$	231.0 (208.0-251.5)
Positive troponin n (%)	12 (17)
NTproBNP (pg/ml) ^a	51.0 (25.0-88.0)
Comorbidities	
Spinal stenosis n (%)	2 (2)
Peripheral neuropathy n (%)	15 (18)
$\frac{1}{CKD} n (\%)$	1 (1)
Bilateral carpal tunnel syndrome n (%)	13 (15)
Pacemaker n (%)	1 (1)
Syncope n (%)	$\frac{1}{2}(2)$
	2 (2)
ECG	
Atrial fibrillation n (%)	3 (4)
AVB n (%)	3 (4)
Low voltage n (%)	1 (1)
Pseudo-infarct pattern n (%)	3 (4)
AI amyloid probability above threshold n (%)	5 (6)
Imaging	
Echocardiography n (%)	80 (94)
PYP scintigraphy n (%)	34 (40)
Cardiac Magnetic Resonance n (%)	4 (5)
Baseline Echocardiographic Features	
LVEF	62.6 (7.4)
Posterior wall thickness (mm)	91(14)
Septal wall thickness (mm)	9.3 (1.5)

LVEDV (ml)	127 (25.7)
LA dilation n (%)	7 (10)
Biatrial dilation n (%)	2 (3)
LAVI (ml/m2)	28 (8.5)
RV dysfunction n (%)	2 (3)
RVSP (mmHg)	27.5 (5.2)
E/e`*	7.7 (2.7)
LV GLS (%)	-20.5 (2.6)
Cono vorients	

Othe variants	
Val30Met n (%)	25 (29)
Thr60Ala n (%)	24 (28)
Val122Ile n (%)	8 (9)
Ile107Val n (%)	6 (7)
Other n (%)	22 (26)

509

510

511 AI: artificial intelligence. AVB: atrioventricular block. CKD: chronic kidney disease. GLS: left

ventricular global longitudinal strain. LVEDV: left ventricle end-diastolic volume. LVEF: left ventricle

513 ejection fraction. LA: left atrium. LAVI: left atrium volume index. PYP: pyrophosphates. RV: right

514 ventricle. RVSP: right ventricle systolic pressure.

*: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not
available, the only septal E/e` was reported.

517 Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.

518 a: Data represent median (1^{st} quantile, 3^{rd} quantile).

519

521 Table 2. Clinical and echocardiographic characteristics in G+/P- ATTRv carriers who had follow-

522 up data available (n=55).

Baseline	Follow-up	Difference	p-value#
2 (3.6)	6 (10.9)	7.3 (-2.3, 16.9)	0.142
10 (18.2)	24 (43.6)	25.5 (8.9, 42.1)	0.004
1 (1.8)	6 (10.9)	9.1 (0.1, 18.1)	0.051
9 (16.4)	16 (29.1)	12.7 (-2.8, 28.2)	0.111
3 (5.5)	8 (14.5)	9.1 (-2, 20.2)	0.112
1 (1.8)	1 (1.8)	-	-
2 (3.6)	8 (14.5)	10.9 (0.4, 21.5)	0.047
63.3 (4.3)	61.2 (3.6)	-2 (-3.6, -0.4)	0.014
9.4 (1.6)	10.2 (2.4)	0.7 (0, 1.3)	0.037
0 (0)	4 (8.7)	8.7 (0.6, 16.8)	0.035
9.3 (1.5)	9.2 (2.2)	0 (-0.5, 0.6)	0.853
0 (0)	2 (4.5)	4.5 (-1.6, 10.7)	0.128
28.5 (9.6)	29.2 (6.8)	1.1 (-2.3, 4.5)	0.518
5 (10.2)	14 (29.8)	19.6 (4, 35.2)	0.016
2 (4.3)	4 (8.9)	4.6 (-5.5, 14.8)	0.368
7.4 (2.2)	7.2 (2.4)	0.3 (-0.6, 1.1)	0.558
-19.8 (2.7)	-20.4 (3)	-0.6 (-1.5, 0.3)	0.205
	Baseline 2 (3.6) 10 (18.2) 1 (1.8) 9 (16.4) 3 (5.5) 1 (1.8) 2 (3.6) 63.3 (4.3) 9.4 (1.6) 0 (0) 9.3 (1.5) 0 (0) 28.5 (9.6) 5 (10.2) 2 (4.3) 7.4 (2.2) -19.8 (2.7)	BaselineFollow-up2 (3.6) 6 (10.9)10 (18.2) 24 (43.6)1 (1.8) 6 (10.9)9 (16.4) 16 (29.1)3 (5.5) 8 (14.5)1 (1.8) 1 (1.8)2 (3.6) 8 (14.5)63.3 (4.3) 61.2 (3.6)9.4 (1.6) 10.2 (2.4)0 (0) 4 (8.7)9.3 (1.5) 9.2 (2.2)0 (0) 2 (4.5)28.5 (9.6) 29.2 (6.8)5 (10.2) 14 (29.8)2 (4.3) 4 (8.9)7.4 (2.2) 7.2 (2.4)-19.8 (2.7) -20.4 (3)	BaselineFollow-upDifference2 (3.6)6 (10.9) 7.3 (-2.3, 16.9)10 (18.2)24 (43.6)25.5 (8.9, 42.1)1 (1.8)6 (10.9)9.1 (0.1, 18.1)9 (16.4)16 (29.1)12.7 (-2.8, 28.2)3 (5.5)8 (14.5)9.1 (-2, 20.2)1 (1.8)1 (1.8)-2 (3.6)8 (14.5)10.9 (0.4, 21.5)63.3 (4.3) 61.2 (3.6) -2 (-3.6, -0.4)9.4 (1.6)10.2 (2.4)0.7 (0, 1.3)0 (0)4 (8.7)8.7 (0.6, 16.8)9.3 (1.5)9.2 (2.2)0 (-0.5, 0.6)0 (0)2 (4.5)4.5 (-1.6, 10.7)28.5 (9.6)29.2 (6.8)1.1 (-2.3, 4.5)5 (10.2)14 (29.8)19.6 (4, 35.2)2 (4.3)4 (8.9)4.6 (-5.5, 14.8)7.4 (2.2)7.2 (2.4)0.3 (-0.6, 1.1) -19.8 (2.7) -20.4 (3) -0.6 (-1.5, 0.3)

523

524 CKD: chronic kidney disease. GLS: left ventricular global longitudinal strain. LV: left ventricular. LVEF:

525 left ventricle ejection fraction.

*: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not available, the only septal E/e` was reported.

528 Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.

529 The proportional difference (95% confidence interval, CI) for binary variables or the mean difference

530 (95% CI) for continuous variables are reported in the column named by "Difference".

531 For binary variables, the proportional difference between follow up and baseline levels was tested if it is

different from 0. For continuous variables, paired t test was used to test if the variable's mean is different

533 between baseline and follow up time. Tow-sided tests were used.

534 #: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account 535 for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/16536 = 0.00313.

538 Table 3. Estimated penetrance for developing cardiac amyloidosis based on various G+/P- ATTRv

539 carrier age groups.

Age Groups*	Total No. of Patients	Penetrance	95% CI
<= 50 years	18	0.11	(0.03, 0.33)
50-60 years	15	0.13	(0.04, 0.38)
60-70 years	15	0.33	(0.15, 0.58)
>= 70 years	7	0.43	(0.16, 0.75)

540 *: the age at the cardiac amyloidosis diagnosis or at the last follow-up.

542 Table 4. Differences between echocardiographic characteristics at baseline and last follow-up

543 among G+/P- ATTRv carriers who developed CA (n = 12).

	Baseline	At CA diagnosis	Difference	p-value#
LVEF	65.2 (3.3)	60.3 (5.3)	-5.2 (-9.6, -0.8)	0.026
Septal wall thickness (mm)	9.4 (1)	12 (3.3)	2.7 (0.6, 4.8)	0.019
Abnormal septal wall thickness n (%)	0 (0)	4 (36.4)	36.4 (7.9, 64.8)	0.034
Posterior wall thickness (mm)	9.8 (1.4)	10.9 (3.3)	1.4 (-0.6, 3.4)	0.147
Abnormal posterior wall thickness n (%)	0 (0)	2 (22.2)	22.2 (-4.9, 49.4)	0.099
Left atrium volume index (ml/m2)	28.2 (10.6)	33.3 (8.1)	6.3 (-3.5, 16.1)	0.173
Left atrium dilation n (%)	1 (9.1)	7 (63.6)	54.5 (21.4, 87.7)	0.008
Biatrial dilation n (%)	0 (0)	3 (33.3)	33.3 (2.5, 64.1)	0.038
E/e`*	8.1 (3.6)	8.6 (4)	2.2 (-1.4, 5.8)	0.198
LV GLS (%)	-19.3 (3.2)	-18 (4.1)	0 (-3.4, 3.5)	0.966

544

545 GLS: left ventricular global longitudinal strain. LV: left ventricular. LVEF: left ventricle ejection fraction.

*: We reported the mean between septal and lateral E/e` when both were available. If lateral E/e` was not
available, the only septal E/e` was reported.

548 Data represent mean (standard deviation, SD) or number (percentage) unless otherwise specified.

549 The proportional difference (95% confidence interval, CI) for binary variables or the mean difference

550 (95% CI) for continuous variables are reported in the column named by "Difference".

551 For binary variables, the proportional difference between follow up and baseline levels was tested if it is

different from 0. For continuous variables, paired t test was used to test if the variable's mean is different

553 between baseline and follow up time. Tow-sided tests were used.

554 #: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account 555 for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/10556 = 0.005.

557

	Estimated HR	95% CI	p-value#
Age (years)	1.09	(1.01, 1.17)	0.0246
Male sex	2.20	(0.66, 7.33)	0.1999
Proband's age	0.91	(0.86, 0.98)	0.0096
Proband`s cardiac involvement	2.56	(0.74, 8.80)	0.1356
Proband`s neuro involvement	0.23	(0.07,0.83)	0.0244
NTproBNP (pg/ml)	1.01	(1.00, 1.01)	0.0187
Peripheral neuropathy	0.89	(0.24, 3.36)	0.8674
Bilateral carpal tunnel syndrome	3.78	(0.89, 15.99)	0.0705
AI amyloid probability at ECG	1.04	(1.01, 1.07)	0.0091
LVEF	1.01	(0.89, 1.15)	0.8778
Posterior wall thickness (mm)	1.41	(0.86, 2.30)	0.1736
Septal wall thickness (mm)	1.08	(0.70, 1.66)	0.7393
Val30Met	0.20	(0.02, 1.56)	0.1230
Thr60Ala	1.68	(0.54, 5.23)	0.3742
Val122Ile	4.96	(0.91, 27.15)	0.0648

559 Table 5. Association between baseline characteristics and ATTRv-CM development risk.

560

561 AI: artificial intelligent; ECG: electrocardiogram; LVEF: left ventricle ejection fraction.

562 *#*: The raw p-value obtained from statistical tests are reported. Bonferroni correction was used to account

for multiple testing. Therefore, the significance level is 0.05, and the adjusted significance level is 0.05/15 = 0.003.

565

567 Figure 1. Kaplan-Meier curve showing the 10-year risk of developing overt ATTRv-CM (29.5%,

568 **95%** CI: 7.9, 46.0).

